Nuvectis Pharma(US:NVCT)2025-11-04 13:16Financial Performance - Net loss for the third quarter of 2025 was $7.5 million, compared to a net loss of $4.2 million for the same period in 2024, reflecting a 80.9% increase[6] - The company reported a basic and diluted net loss per common share of $0.44 for the third quarter of 2025, compared to $0.24 for the same period in 2024[15] Cash and Liquidity - Cash and cash equivalents increased to $35.4 million as of September 30, 2025, up from $18.5 million as of December 31, 2024, representing a 91.5% increase[4] - Interest income for the third quarter of 2025 was $0.3 million, compared to $0.2 million for the same period in 2024, indicating a 50% increase[8] - The cash runway is projected to support the company's operations into the third quarter of 2027[5] Research and Development - Research and development expenses rose to $5.8 million for the third quarter of 2025, up from $2.8 million in the same quarter of 2024, marking a 107.1% increase[7] - The company completed the NXP900 Phase 1a dose escalation study, demonstrating robust pharmacodynamic responses at clinically relevant doses[5] - The NXP900 Phase 1b program has been initiated, with the single agent study currently underway and the combination portion expected to start by year-end[5] Balance Sheet - Total liabilities as of September 30, 2025, were $11.6 million, compared to $8.9 million as of December 31, 2024, reflecting a 30.5% increase[13] - The total shareholders' equity increased to $24.0 million as of September 30, 2025, up from $9.7 million as of December 31, 2024, representing a 147.0% increase[13]